{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:31:43Z","timestamp":1791613903601,"version":"4.3.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Immune-related adverse events frequently take place after initiation of immune checkpoint inhibitors (ICI) therapy. The thyroid gland is the endocrine organ most commonly affected by ICI therapy, the pathological mechanism is still poorly understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Description<\/jats:title><jats:p>A 60-year old Upper Austrian male melanoma patient under pembrolizumab therapy received thyroidectomy because of a suspicious FDG avid thyroid nodule. Histopathology showed a pattern comparable with thyroiditis de Quervain. The inflammatory process consisted predominantly of T lymphocytes with a dominance of CD4+ T helper cells. In addition CD68+ histiocytes co-expressing PD-L1 were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clusters of perifollicular histiocytes expressing PD-L1 were observed in this case of pembrolizumab induced thyroiditis - probably induced by the former ICI therapy. This finding might indicate the initial target for the breakdown of self tolerance. In context with other data the immunological process seems to be driven by CD3+ lymphocytes infiltrating the thyroid.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.606056","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T07:17:01Z","timestamp":1624000621000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"J\u00f6rg","family":"Jabkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almute","family":"Loidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Auinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Kehrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Sepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01430","article-title":"Pd-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-019-9579-2","article-title":"Pembrolizumab-Induced Thyroiditis","volume":"30","author":"Imblum","year":"2019","journal-title":"Endocr Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819896182","article-title":"Immunotherapy-Induced Endocrinopathies: Assessment, Management and Monitoring","volume":"10","author":"Nogueira","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK Cell-Based Immune Checkpoint Inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S261433","article-title":"Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review","volume":"13","author":"El El Sabbagh","year":"2020","journal-title":"Int J Gen Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-a Comprehensive Review","author":"Hommes","year":"2021","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated With Immune Checkpoint Inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0216954","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, Features, and Prognosis of Immune-Related Adverse Events Involving the Thyroid Gland Induced by Nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10466","article-title":"Clinical Features of Immune-Related Thyroid Dysfunction and its Association With Outcomes in Patients With Advanced Malignancies Treated by PD-1 Blockade","volume":"18","author":"Sakakida","year":"2019","journal-title":"Oncol Lett"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000501824","article-title":"Graves\u2019 Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature","volume":"8","author":"Brancatella","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13044-018-0058-5","article-title":"Correlation Between Anti-Thyroid Peroxidase Antibody Levels and Diffuse Thyroid Uptake of 18F-Fluorodeoxyglucose in Hashimoto\u2019s Thyroiditis: A Retrospective Study","volume":"11","author":"Edo","year":"2018","journal-title":"Thyroid Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00292-016-0157-9","article-title":"Entz\u00fcndungen Der Schilddr\u00fcse [Inflammatory Diseases of the Thyroid Gland]","volume":"37","author":"Synoracki","year":"2016","journal-title":"Pathologe"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5246516","article-title":"Cytomorphological Spectrum of Thyroiditis: A Review of 110 Cases","volume":"2018","author":"Chandanwale","year":"2018","journal-title":"J Thyroid Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","article-title":"Analysis of the PD-1\/PD-L1 Axis in Human Autoimmune Thyroid Disease: Insights Into Pathogenesis and Clues to Immunotherapy Associated Thyroid Autoimmunity","volume":"103","author":"\u00c1lvarez-Sierra","year":"2019","journal-title":"J Autoimmun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive Screening for PD-L1 Expression in Thyroid Cancer","volume":"24","author":"Ahn","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/1758834017749748","article-title":"Interferon Gamma, an Important Marker of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer and Melanoma Patients","volume":"10","author":"Karachaliou","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2087525","article-title":"Treatment of Ipilimumab Induced Graves\u2019 Disease in a Patient With Metastatic Melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0418","article-title":"Histology of Nivolumab-Induced Thyroiditis","volume":"12","author":"Neppl","year":"2018","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","first-page":"E3934","DOI":"10.3390\/ijms20163934","article-title":"The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition","volume":"20","author":"Varricchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and Sensitive Biomarkers for Thyroid Dysfunctions During Treatment With Immune-Checkpoint Inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","article-title":"Immune Checkpoint Inhibitor-Induced Thyroiditis is Associated With Increased Intrathyroidal T Lymphocyte Subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events\u2014a Comprehensive Review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1249559","DOI":"10.1080\/2162402X.2016.1249559","article-title":"Clinical Implication of Tumor-Associated and Immunological Parameters in Melanoma Patients Treated With Ipilimumab","volume":"5","author":"Damuzzo","year":"2016","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.606056\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T07:17:03Z","timestamp":1624000623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.606056\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2021.606056"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.606056","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"article-number":"606056"}}